Glioma is a primary malignancy of the central nervous system (CNS). As biomedicine advances, an efficient molecular target is urgently needed for the diagnosis and treatment of glioma. Meanwhile, several studies have demonstrated that glioma development is closely related to immunity. PARP9 is an inactive mono‐ADP‐ribosyltransferase belonging to the poly‐ADP ribosyltransferase (ARTD) family. In this article, we aimed to reveal the relationship between PARP9 and glioma and explore the potential prognostic value and immunotherapeutic targetability of PARP9 in glioma.

中文翻译：

---

胶质瘤中 PARP9 的分子和临床特征：潜在的免疫治疗靶点。

神经胶质瘤是中枢神经系统 (CNS) 的原发性恶性肿瘤。随着生物医学的进步，神经胶质瘤的诊断和治疗急需一种有效的分子靶点。同时，多项研究表明，胶质瘤的发展与免疫密切相关。PARP9 是一种无活性的单 ADP 核糖基转移酶，属于多聚 ADP 核糖基转移酶 (ARTD) 家族。在本文中，我们旨在揭示 PARP9 与神经胶质瘤之间的关系，并探讨 PARP9 在神经胶质瘤中的潜在预后价值和免疫治疗靶向性。